Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Heplisav-B
Pharma
Sanofi bolsters adult vaccine roster with $2.2B Dynavax purchase
Following an activist investor feud earlier this year, vaccine developer Dynavax Technologies has agreed to sell itself to France’s Sanofi.
Fraiser Kansteiner
Dec 29, 2025 10:24am
FDA approves VBI's PreHevbrio just as HBV market is set to grow
Dec 1, 2021 10:34am
Efficacy, convenient dosage give Dynavax's Heplisav-B an edge
Nov 5, 2021 7:00am
Heplisav-B; Janssen and more—News of Note
Feb 27, 2019 9:14am
Dynavax, Emergent and more—News of Note
Aug 8, 2018 7:59am
FluMist, Heplisav-B and more—News of Note
Feb 21, 2018 8:46am
